1. Market Research
  2. > Pathology
About 100 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • February 2020
  • 163 pages

R. (2016) ' B CELLS GONE ROGUE: THE INTERSECTION OF DIFFUSE LARGE B CELL LYMPHOMA AND AUTOIMMUNE DISEASE', EXPERT REVIEW OF HEMATOLOGY, ##(##), PP. ##-##.

  • Genitourinary System Disease
  • Hospital
  • Lymphoma
  • Musculoskeletal Disorder
  • Therapy

Global Auto-Injectors Market (By Application/Indication, Product Type, Usability, Distribution Channels, Region), Key Company Profiles - Forecast to 2025

  • $ 1990
  • August 2019
  • 126 pages

lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD## therapies pursuant to its collaboration arrangements with Genentech, Inc.

  • Injectable Delivery
  • Lymphoma
  • Musculoskeletal Disorder
  • World
  • Amgen Inc.

Global Autoimmune Disease Diagnostic Market (By Disease, Tests Type, Regions), Key Company Profiles - Forecast to 2026

  • $ 1890
  • November 2019
  • 137 pages

lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

  • Autoimmune Disease
  • Diagnostics
  • Lymphoma
  • Musculoskeletal Disorder
  • World

Global Sterile Injectables Market – Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2023 - Molecule Type, Drug Type, Indication, Channel

  • $ 2400
  • June 2018
  • 240 pages

lymphoma Diffuse large B-cell lymphoma Diffuse large B-cell lymphoma Pfizer Utomilumab Human IgG## CD## Phase ## Hoffmann-La Roche Polatuzumab vedotin Humanized IgG## ADC CD##b Phase ## Viventia Bio Oportuzumab monatox Humanized scFv immunotoxin EpCAM Phase ## Bladder cancer S

  • Endocrine Disease
  • Lymphoma
  • Musculoskeletal Disorder
  • World
  • Baxter International Inc.

Pharmaceutical Drugs Global Market Report 2018

  • $ 8000
  • March 2018
  • 455 pages

Its importance results from the large population of cancer patients suffering from various types of blood cancers such as leukemia, lymphoma, and myeloma.

  • Healthcare
  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Market Size

Rheumatoid Arthritis: Epidemiology Forecast to 2027

  • $ 3995
  • January 2019
  • 46 pages

Rheumatoid Arthritis: Epidemiology Forecast to 2027 Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint defo ...

  • Arthritis
  • Lymphoma
  • Musculoskeletal Disorder
  • United States
  • Forecast

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

  • $ 2500
  • November 2016
  • 98 pages

It has many comorbidities related to it such as diabetes, metabolic disorders, chronic respiratory diseases, lymphomas, hypertension, and other cardiovascular disorders.

  • Cancer Immunotherapy
  • Lymphoma
  • Musculoskeletal Disorder
  • Therapy
  • AbbVie Inc.

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

  • $ 2500
  • August 2016
  • 120 pages

IT HAS COMORBIDITIES SUCH AS PSORIASIS, DIABETES, HYPERTENSION AND OTHER CARDIOVASCULAR DISORDERS, METABOLIC DISORDERS, AND LYMPHOMAS.

  • Autoimmune Disease
  • Lymphoma
  • Musculoskeletal Disorder
  • Therapy
  • World

Regenerative Medicine Market by Type, Applications, Region - Global Forecast to 2024

  • $ 4950
  • March 2019
  • 108 pages

The cell-based immunotherapy & cell therapy products segment is further segmented into allogeneic Kite Pharma/ Gilead (US) Cell-based immunotherapy (CAR T-cell therapy) Treatment of B-cell malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, mantle cell

  • Cell Therapy
  • Lymphoma
  • Musculoskeletal Disorder
  • Regenerative Medicine
  • United States

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 173 pages

It is in Phase I stage of development for B-cell lymphomas such as diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma as second-line therapy in Japan.

  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • Galapagos NV

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • January 2017
  • 407 pages

B CELLS GONE ROGUE: THE INTERSECTION OF DIFFUSE LARGE B CELL LYMPHOMA AND AUTOIMMUNE DISEASE.

  • Epidemiology
  • Hospital
  • Lymphoma
  • Musculoskeletal Disorder
  • Therapy

Global Bone Densitometer Market 2016-2020

  • $ 2500
  • September 2016
  • 68 pages

Chronic disease causing bone disorders Disease Description LEUKEMIA AND LYMPHOMA Treatment using drugs can result in bone loss AIDS/ HIV LOW BLOOD SUGAR Increased risk of falling Treatment using drugs can result in bone loss, which can potentially increase over a period of time PITUITAR

  • Diagnostic Imaging
  • Lymphoma
  • Musculoskeletal Disorder
  • World
  • Hologic, Inc.

Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 138 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Autoimmune Disease
  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy

Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 241 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Hospital
  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy

Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 244 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Hospital
  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy

Gouty Arthritis (Gout) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 132 pages

It also provides treatment for arginine dependent cancers such as prostate cancer, leukemia, metastatic melanoma, lymphoma, sarcoma and pancreatic cancer, among others.

  • Arthritis
  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy

Nephrotic Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 46 pages

lymphoma, chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener s Granulomatosis), follicular lymphoma, pemphigus vulgaris, liver transplant rejection, vasculitis, idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura), nephrotic syndrom

  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • United States

Pigmented Villonodular Synovitis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 48 pages

AS OF APRIL 2018, IT WAS IN PHASE I STAGE FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.

  • Hospital
  • Lymphoma
  • Musculoskeletal Disorder
  • Pathology
  • Therapy

T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 88 pages

T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019 Summary T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation ...

  • Immunotherapy
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Therapy
  • Bristol-Myers Squibb Company

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018

  • $ 3500
  • May 2018
  • 155 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Arthritis
  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
View report >

Sexually Transmitted Disease Statistics in the US and North America

  • January 2019
  • 71 pages

HEALTH CARE ACCESSDINGS Access to health care is defined in Ohio' s 2016 State Health Improvement Plan as, " having timely use of comprehensive, integrated, and appropriate heath services to achieve the best outcomes. "

  • Lymphoma
  • Musculoskeletal Disorder
  • Sexually Transmitted Disease
  • North America
  • United States

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on